Now PARP inhibitors have demonstrated efficacy in a number of tumor types, including platinum-sensitive epithelial ovarian cancer [50], breast cancer with mutation in BRCA1 or BRCA2 [91], and prostate cancer [92]. Here, PARP1 is linked to neoplasm.